Induction of P-glycoprotein and cytochrome P450 3a by HIV protease inhibitors

Drug Metabolism and Disposition

Volumn 29, Issue 5, 2001, Pages 754-760

  Huang, Liyue ^a   Wring, Stephen A ^a   Woolley, Joseph L ^a   Brouwer, Kenneth R ^a   Serabjit Singh, Cosette ^a   Polli, Joseph W ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; CYTOCHROME P450 3A; GLYCOPROTEIN; NELFINAVIR; PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; ENZYME INDUCTION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; CARBAMATES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HIV PROTEASE INHIBITORS; HUMANS; INTESTINES; LIVER; MALE; NELFINAVIR; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; RATS; RATS, WISTAR; SULFONAMIDES; TUMOR CELLS, CULTURED;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0035029345     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
2. Nelfinavir: An update on its use in HIV infection
3. mdr2 encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies
4. Identification of a sister gene to P-glycoprotein
5. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions
6. Dexamethasone modulation of multidrug transporters in normal tissues
7. HIV protease inhibitors
8. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies
9. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver
10. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
11. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4
12. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
13. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
14. Pharmacokinetics interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum)
15. A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes. Their use in investigating some properties of D-glucose and choline transport systems
16. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
17. CY3A gene expression in human gut epithelium
18. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
19. Metabolism of digoxin, digoxigenin, digitoxosides, and digoxigenin in human hepatocytes and liver microsomes
20. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
21. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate
22. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450 A and P-glycoprotein induction
23. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test
24. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein
25. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
26. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
27. In vivo effect of α1-acid glycoprotein on the pharmacokinetics of amprenavir, a HIV protease inhibitor
28. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers
29. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulated these proteins in human colon carcinoma cells
30. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes
31. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
32. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound
33. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
34. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis
35. Overlapping substrate specificities and tissue distribution of cytochrome P-450 3A and P-glycoprotein: Implications for drag delivery and activity in cancer chemotherapy
36. Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man
37. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction
38. Oral absorption of the HIV protease inhibitors: A current update
39. Automated dual LC/MS/MS with cassette analysis markedly increases throughput and accelerates drug discovery